Last updated: February 20, 2026
What is NDC 24385-0485?
NDC 24385-0485 refers to Mounjaro (tirzepatide), a treatment approved by the U.S. Food and Drug Administration (FDA) in May 2022 for managing type 2 diabetes mellitus. This drug is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. It is administered as a once-weekly injection.
Market Size and Demand Drivers
Current Market Landscape
- Diabetes prevalence: An estimated 37.3 million Americans (about 11.3%) have diagnosed diabetes (CDC, 2020).
- Market segment: The global type 2 diabetes drugs market was valued at USD 54.4 billion in 2021.
- Growth rate: Compound annual growth rate (CAGR) of 8.2% from 2022 to 2030 (Grand View Research, 2022).
Competitive Position
- NDC 24385-0485 competes primarily with drugs such as semaglutide (Wegovy, Ozempic), dulaglutide (Trulicity), and liraglutide (Victoza).
- Its dual mechanism offers potential advantages for weight loss and glycemic control, making it attractive for expanding patient segments.
Broader Indications
- Emerging evidence supports tirzepatide's use for obesity management, broadening the market beyond diabetes.
- FDA approval for obesity is under review, with anticipated decision in mid-2023.
- These expansions could increase annual sales volume by 25-40% within 3-5 years.
Price Points and Revenue Estimates
Current Pricing
- Average wholesale price (AWP): Approximately USD 1,035 per 4-week supply (Drug Channels, 2023).
- List price comparison: Slightly higher than semaglutide (Ozempic, ~USD 860) due to its dual action.
Revenue Projections
- 2023: Estimated sales of USD 2.4 billion globally.
- 2025: Projected to reach USD 4.3 billion, assuming continued market penetration and approval for obesity indication.
- Market share assumptions: NDC 24385-0485 captures 25-30% of the GLP-1-like market within 2 years.
Pricing Scenarios
| Scenario |
Price per 4-Week Supply |
Expected Global Sales (USD) |
Market Share |
Timeline |
| Conservative |
USD 1,035 |
USD 2.4 billion |
25% |
2023 |
| Moderate |
USD 1,250 |
USD 3.0 billion |
30% |
2024 |
| Aggressive |
USD 1,500 |
USD 4.3 billion |
40% |
2025 |
Price Elasticity Considerations
- The price premium over competitors is justified by superior efficacy and manufacturing complexity.
- Patient affordability and insurance coverage remain critical factors influencing actual transaction prices.
Regulatory and Market Expansion Factors
- Approval for obesity and other indications could drive significant volume increases.
- Entry into emerging markets (e.g., China, India) could expand total addressable market by approximately 15-20%.
- Patent exclusivity until at least 2030 supports sustained pricing power.
Competitive and Patent Outlook
- Patent protections on tirzepatide formulations are active until 2030 under U.S. law, with certain formulations possibly extending to 2035 through extensions.
- Biosimilar competition unlikely before 2027 due to high barriers; biosimilar entrants could press prices downward thereafter.
Risks and Challenges
- Healthcare policy shifts toward price regulation could temper price growth.
- Increasing competition from other dual-acting agents or oral formulations may reduce market share.
- Adverse events or safety concerns could impact reimbursement and demand.
Key Takeaways
- NDC 24385-0485 (tirzepatide) is positioned for continued rapid sales growth driven by expanding indications and favorable market dynamics.
- Current prices are around USD 1,035 per 4-week supply, with potential to rise in new indications and markets.
- Sales are projected to reach USD 4.3 billion globally by 2025 under aggressive pricing and market penetration scenarios.
- Patent protections until 2030 sustain pricing power, though biosimilar threats could emerge after that year.
- Pricing strategies will depend on payer negotiations, competitive pressures, and regulatory developments.
FAQs
1. What factors influence the pricing of tirzepatide (NDC 24385-0485)?
Pricing depends on manufacturing costs, competitive positioning, patent protections, reimbursement negotiations, and the drug’s efficacy and safety profile.
2. How does tirzepatide compare cost-wise to similar GLP-1 receptor agonists?
It is priced higher (around USD 1,035 per 4-week supply) than drugs like semaglutide (~USD 860) due to its dual mechanism and market positioning.
3. What are the main risks to revenue projections for this drug?
Regulatory changes, safety concerns, increased competition, and insurance coverage limits could reduce sales growth.
4. When are biosimilars expected to impact tirzepatide prices?
Biosimilar competition is unlikely before 2027, but could influence prices after patent expiration, potentially reducing prices by 20-40%.
5. What is the potential market impact of expanding tirzepatide into obesity treatment?
Approval for obesity could triple current diabetes-related sales, adding an estimated USD 1-2 billion annually globally by 2025.
References
- Centers for Disease Control and Prevention (CDC). (2020). National Diabetes Statistics Report.
- Grand View Research. (2022). Diabetes Drugs Market Size, Trends, and Forecasts.
- Drug Channels Institute. (2023). Average Wholesale Price Data.
